News | 03 December 2025
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
FDA's withholding of the PRV was contrary to law because no drug product containing phenobarbital sodium was 'previously approved'
Now a test that offers new precision in prostate cancer detection
Patients can now get the starting 2.5 mg dose for $299 per month
At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
LANXESS Biosecurity Solutions aims to deliver “advanced disinfection and hygiene solutions to support Indian farmers in maintaining healthier and safer farm environments
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
Abdomen-pelvis CT is the nation’s highest-volume CT category
The receipt of this order further strengthens the company's position in the global pharmaceutical market
Amrutanjan is also rolling out its new campaign, 'Har Dard Mitaye'
This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
GV20 received an upfront payment and is eligible for additional milestone payments
The fresh capital will propel Cordance into its first-in-human clinical trial
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
Subscribe To Our Newsletter & Stay Updated
